Novartis AG Logo

Novartis AG

Develops and markets innovative medicines globally using advanced science and technology.

NOVN | SW

Overview

Corporate Details

ISIN(s):
CH0012005267 (+10 more)
LEI:
5493007HIVTX6SY6XD66
Country:
Switzerland
Address:
LICHTSTR. 35, 4056 BASEL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Novartis AG is a global innovative medicines company dedicated to the research, development, manufacturing, and marketing of a broad range of healthcare products. The company's core mission is to reimagine medicine to improve and extend people's lives. By utilizing advanced science and digital technologies, Novartis focuses on creating transformative treatments in areas of significant medical need. Its portfolio serves patients, healthcare professionals, and societies worldwide through the development of pharmaceuticals and other therapeutic solutions.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Novartis AG and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-08-07 08:30
Major Shareholding Notification
Obvestilo o spremembi pomembnega deleža družbe Sandoz AG
Slovene 2.2 MB
2023-08-07 08:30
Major Shareholding Notification
Obvestilo o spremembi pomembnega deleža družbe Novartis Pharma AG
Slovene 4.4 MB
2023-08-07 08:30
Major Shareholding Notification
Obvestilo o spremembi pomembnega deleža
Slovene 2.4 KB
2019-10-22 08:00
Earnings Release
Novartis delivered another strong quarter with double digit sales growth and co…
English 138.9 KB
2019-10-08 08:15
Regulatory News Service
Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gai…
English 28.9 KB
2019-10-02 08:15
Regulatory News Service
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing…
English 21.0 KB
2019-09-29 17:30
Earnings Release
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3…
English 25.3 KB
2019-09-17 08:15
Legal Proceedings Report
Novartis Cosentyx® positive 16-week PREVENT results advance potential new indic…
English 24.4 KB
2019-08-30 08:15
Regulatory News Service
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-hea…
English 24.4 KB
2019-07-29 08:00
Regulatory News Service
Novartis provides update on Phase III PARAGON-HF trial in heart failure patient…
English 29.7 KB
2019-07-18 08:00
Earnings Release
Novartis delivers strong sales, double digit core operating income growth and l…
English 137.7 KB
2019-07-01 18:30
M&A Activity
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic p…
English 19.0 KB
2019-06-07 08:00
Board/Management Information
Novartis announces new leader of Pharmaceuticals Business Unit
English 18.1 KB
2019-04-24 08:00
Earnings Release
Novartis starts 2019 with strong sales and double digit core1 operating income …
English 95.6 KB
2019-03-27 00:35
Regulatory News Service
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to…
English 27.7 KB

Automate Your Workflow. Get a real-time feed of all Novartis AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Novartis AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-30 N/A Executive member Sell None 1,973,993.83 CHF
2025-03-07 N/A Non-Executive member Buy None 160,000.00 CHF
2025-02-11 N/A Executive member Sell None 312,203.18 CHF
2025-02-07 N/A Executive member Sell None 2,500,278.74 CHF
2025-02-05 N/A Executive member Sell None 1,365,687.19 CHF
2025-02-04 N/A Executive member Sell None 1,840,201.00 CHF
2025-01-30 N/A Executive member Buy None 699,424.74 CHF
2025-01-30 N/A Executive member Buy None 698,883.18 CHF
2024-12-19 N/A Executive member Sell None 1.00 CHF
2024-11-29 N/A Executive member Sell None 167,294.98 CHF

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.